hotspot -WSS

hotspot

author：fashion 2025-09-28 00:52:52 - browse：2359

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： A new drug could help frostbite victims avoid its ravages

WSS

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Parkinson’s finding may lead to tests and, someday, treatments

Copay coupons to count toward deductibles, after Biden court move

Weight loss drugs aren’t covered by Obamacare. That may change

Hospitals are piloting generative AI tools as regulators play catch

Weight loss drugs aren’t covered by Obamacare. That may change

focus

hotspot

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

In Memoriam: Notable people who died in 2023

Francis Collins on trust in science and how Covid communications failed

Alkermes shareholders re

MD Anderson's Padmanee Sharma responds to research credit suit

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

eGenesis tests gene

Alkermes shareholders re

How digital therapeutics firms are pivoting after Pear's bankruptcy

Wikipedia

My yearlong odyssey to get my son’s ADHD medication covered

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Research misconduct: Proposed new rules face resistance

Medicare Advantage enrollment grows 7.1% to 33.4 million people

WATCH: Why do our ears pop?

Eli Lilly, Pfizer, and others want in on the online prescription market

leisure time

hotspot

hotspot

entertainment